Eli Lilly's Phase 3 obesity drug trial shows substantial weight loss

What This is

• Eli Lilly’s experimental once-weekly obesity injection retatrutide produced unusually large average weight loss in a Phase 3 trial and is being positioned as a next-generation alternative to current GLP-1 drugs.
• In the TRIUMPH-1 study of 2,339 adults with overweight or obesity, the 12 mg dose led to about 28.3% average body-weight loss over 80 weeks versus about 2.2% with placebo, and roughly 45% of participants lost at least 30%.
• Lower doses also produced substantial weight loss, with reports citing roughly 19% at 4 mg and about 25–26% at 9 mg over the same treatment period.
• Retatrutide is a “triple agonist” that targets GLP-1, GIP, and glucagon hormone receptors, a design intended to deliver more weight loss than drugs that target fewer pathways.
• Eli Lilly reported improvements in cardiometabolic risk markers alongside weight loss, and some coverage noted that many participants moved below the clinical obesity threshold of BMI 30.
• Side effects were largely gastrointestinal and dose-related, with nausea, vomiting, diarrhea, constipation, and an adverse-event discontinuation rate of about 11% at the highest dose.
• An extension in people with more severe obesity reported average weight loss of about 30% over roughly two years of treatment.
• Lilly said it plans to seek regulatory approval, with some outlets describing a possible U.S. filing as soon as this year and others indicating a target launch next year.

Why This Matters

• If safety and durability hold up, a drug delivering near–bariatric-surgery levels of weight loss could reshape standard medical care for obesity.
• Higher discontinuation from side effects underscores the real-world tradeoff between maximum weight loss and how many patients can tolerate long-term treatment.
• Stronger medications may widen equity gaps if access depends on insurance coverage, national health-system eligibility rules, or out-of-pocket payment.
• Large population uptake could shift health-system spending by reducing obesity-related complications while increasing demand for chronic, high-cost medicines.